uniQure N.V. (QURE) Receives Consensus Rating of “Hold” from Brokerages
uniQure N.V. (NASDAQ:QURE) has received a consensus rating of “Hold” from the nine brokerages that are currently covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, three have issued a hold rating and five have given a buy rating to the company. The average 12-month price objective among brokerages that have issued ratings on the stock in the last year is $15.50.
A number of research analysts have recently commented on QURE shares. Zacks Investment Research lowered uniQure N.V. from a “hold” rating to a “sell” rating in a report on Wednesday, October 18th. Chardan Capital set a $13.00 price target on uniQure N.V. and gave the company a “buy” rating in a report on Sunday, July 23rd. Leerink Swann raised their price target on uniQure N.V. from $17.00 to $19.00 and gave the company an “outperform” rating in a report on Friday, October 20th. Finally, ValuEngine lowered uniQure N.V. from a “hold” rating to a “sell” rating in a report on Tuesday, August 1st.
ILLEGAL ACTIVITY WARNING: This news story was first posted by American Banking News and is the property of of American Banking News. If you are accessing this news story on another site, it was copied illegally and reposted in violation of United States and international trademark & copyright laws. The legal version of this news story can be read at https://www.americanbankingnews.com/2017/11/02/uniqure-n-v-qure-receives-consensus-rating-of-hold-from-brokerages.html.
uniQure N.V. (NASDAQ:QURE) last issued its quarterly earnings results on Tuesday, August 8th. The biotechnology company reported ($0.83) EPS for the quarter, missing analysts’ consensus estimates of ($0.78) by ($0.05). The business had revenue of $4.94 million for the quarter, compared to analyst estimates of $2.92 million. uniQure N.V. had a negative net margin of 289.94% and a negative return on equity of 131.27%.
A number of large investors have recently added to or reduced their stakes in the stock. Mangrove Partners acquired a new position in uniQure N.V. during the second quarter worth about $247,000. FMR LLC grew its holdings in uniQure N.V. by 4.1% during the second quarter. FMR LLC now owns 1,560,113 shares of the biotechnology company’s stock worth $9,656,000 after acquiring an additional 61,650 shares during the period. JPMorgan Chase & Co. grew its holdings in uniQure N.V. by 33.5% during the second quarter. JPMorgan Chase & Co. now owns 58,481 shares of the biotechnology company’s stock worth $362,000 after acquiring an additional 14,659 shares during the period. Paloma Partners Management Co grew its holdings in uniQure N.V. by 717.7% during the first quarter. Paloma Partners Management Co now owns 85,000 shares of the biotechnology company’s stock worth $491,000 after acquiring an additional 74,605 shares during the period. Finally, Renaissance Technologies LLC grew its holdings in uniQure N.V. by 48.8% during the first quarter. Renaissance Technologies LLC now owns 374,000 shares of the biotechnology company’s stock worth $2,162,000 after acquiring an additional 122,700 shares during the period. 29.96% of the stock is currently owned by hedge funds and other institutional investors.
About uniQure N.V.
Uniqure NV is a gene therapy company based in the Netherlands. The Company is engaged in the discovery, development and commercialization of single treatments with curative results for patients suffering from genetic and other severe diseases. The Company advances a focused pipeline of gene therapies that are developed both internally and through partnerships.
Receive News & Ratings for uniQure N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for uniQure N.V. and related companies with MarketBeat.com's FREE daily email newsletter.